donor. GVHD prophylaxis consisted of T cell depletion of the donor marrow with T10-B9 (an anti-␣␤ heterodimer T cell IgM monoclonal antibody), and rabbit complement, We report a patient who developed breast masses 17 months after a T cell-depleted partially mismatched followed by post-BMT immunosuppression with cyclosporine, prednisone, and antithymocyte globulin. Her transplant related donor (PMRD) bone marrow transplant (BMT) for chronic myeloid leukemia. The patient had severe course was uneventful and she had sustained engraftment. On day +155 skin manifestations of chronic GVHD chronic graft-versus-host disease (GVHD) and the masses were due to Epstein-Barr virus (EBV) lymphoappeared after tapering steroid therapy. Immunosuppression with cyclosporine and prednisone was increased and azathiproliferative disease (LPD). The patient expired from fungal pneumonia after chemotherapy for the EBVoprine was added. Azathioprine resulted in leukopenia and the patient discontinued the drug herself. She was main-LPD.
ease; bone marrow transplant; graft-versus-host disease In March 1996, she noticed discrete non-tender nodules in the left breast on self-examination. A surgical consultation was obtained but excision was deferred in view of Graft-versus-host disease (GVHD) remains one of the chronic skin GVHD. A needle biopsy of the breast nodules major complications of allogeneic BMT. 1 Measures to was performed. Pathological examination showed a prereduce GVHD have included T cell depletion of donor dominantly B cell infiltrate, which was of donor origin as graft, and the use of immunosuppressants. However these determined by fluorescent in situ hybridization (FISH) measures give rise to opportunistic infections and secondanalysis for the Y chromosome. The changes were thought ary malignancies, including EBV-LPD. 2, 3 We report a to represent lymphocytic mastitis. 4 Immunosuppression patient with underlying severe chronic GVHD who with alternate day cyclosporine and prednisone was condeveloped EBV-LPD of the breast, late after T-depleted tinued. The breast nodules, however, gradually increased in BMT.
size and became tender. No adenopathy was detected on examination, or on CT scans of the neck, chest and abdomen ( Figure 1a ). An excisional biopsy of one of the breast Case report lumps revealed histopathological findings consistent with a high-grade lymphoma ( Figure 2a and b), predominantly B A 25-year-old female was diagnosed with chronic myelocell type ( Figure 2c ). PCR testing showed positivity for genous leukemia in July 1994 when a blood test on routine EBV DNA. Donor leukocyte infusion (DLI) was deferred physical examination showed a white blood cell count in view of the chronic GVHD and the patient was treated (WBC) of 544 × 10 6 /l. A bone marrow aspiration and cytowith high-dose CHOP (cyclophosphamide, doxorubicin, genetic analysis confirmed chronic myelogenous leukemia vincristine and prednisone) chemotherapy, with reduction with the 9:22 chromosomal translocation. She was treated in the size of the breast lumps (Figure 1b) . The post-chemowith hydroxyurea. No HLA-matched donor was identified therapy course, however, was complicated by Aspergillus in the family or in donor registries. She elected to undergo pneumonia, which was fatal. a PMRD BMT in October 1994, using her father as the first 6 months after transplant 5, 6 and are seen in lymph nodes areas although organ involvement including the lung and the central nervous system is described. 7 There has been no case reported in the literature that involved the breast tissue. The risk of developing EBV-LPD increases several-fold with the use of unrelated or HLA-mismatched donors, probably due to T cell depletion of the marrow graft and greater use of immunosuppressants. In the majority of affected cases, the tumor cells are of donor origin. 5, 6 Treatment options for EBV-LPD have included discontinuation of immunosuppression, antiviral therapy with acyclovir, alpha-interferon, immunoglobulin, and unirradiated dren's Research Hospital for the generation of EBVspecific cytotoxic T cells whilst she was receiving CHOP treatment. Unfortunately, she died before the targeted lymphocytes could be made available. Since discontinuation of immunosuppression and adminimprovement in the breast mass after one cycle of highdose CHOP. However, prolonged neutropenia resulted in istration of DLI was not a feasible option for our patient in view of progressive chronic GVHD, we elected to use fatal fungal pneumonia, illustrating the difficulties in giving anti-neoplastic therapy to post-BMT patients with GVHD. chemotherapy, as has been described. 10 There was clinical
